



7th GO & 7th MEMAGO

Middle East & Mediterranean Association
of Gynecologic Oncologist

December 7-8, 2023
Egypt

www.memago.org



7th GO & 7th MEMAGO

Middle East & Mediterranean Association
of Gynecologic Oncologist

December 7-8, 2023
Egypt

BOARD of DIRECTORS

PRESIDENT

Ali Ayhan, TURKEY

CO-PRESIDENT

Georges Chahine, LEBANON

VICE PRESIDENT

Mehmet Faruk Köse, TURKEY

CO-VICE PRESIDENT

Muhieddine Seoud, LEBANON

SECRETARY

Mehmet Mutlu Meydanlı, TURKEY

CO-SECRETARY

David Atallah, LEBANON

TREASURER

Çağatay Taşkiran, TURKEY

CO-TREASURER

Monia Hechiche, TUNISIA

MEMBER

Nejat Özgül, TURKEY
Mete Güngör, TURKEY
Müfit Cemal Yenen, TURKEY
Hüsnü Çelik, TURKEY

CO-MEMBER

Basel Refky, EGYPT
Waleed El Jassar, KUWAIT
Karim El Masri, U.A.E.
Jamel Ben Hassouna, TUNISIA

PROGRAM

Thursday 7th, December 2023

9h30-10h00 **Welcome and introduction**

MEMAGO President

EGOS Chair

Ali Ayhan

El-Said Abdel-Hady

Session 1: Prevention and Screening of Cervical Cancer

10h00-10h20 Screening for cervical cancer: Has MEMAGO adapted?

10h20-10h40 HPV vaccines: Real world efficacy

10h40-11h00 Can cervical cancer be eliminated in the MEMAGO region:
How best to combine screening and vaccination?

11h00-11h15 Discussion

Session 2: Challenges in the Treatment of Cervical Cancer

11h15-11h35 Early-stage cervical cancer: Is less radical surgery better?

11h15-11h25 Yes

11h25-11h35 No

11h35-11h55 Minimally invasive surgery (MIS) for early-stage cervical cancer: The ongoing debate

11h35-11h45: It is still safe

11h45-11h55: It should not be the standard of care

11h55-12h15 Adjuvant treatment of intermediate-risk cervical cancer patients: Can we do more?

12h15-12h35 Neoadjuvant therapy for the management of bulky (> 4cm) tumors

12h15-12h25 PRO

12h25-12h35 CON

12h35-12h55 Updates for the management of advanced and recurrent cervical cancer

12h55-13h10 Surgery in locally advanced and in residual disease post concurrent chemoradiotherapy

13 h10-13h20 Discussion

13h20-14h20

LUNCH

Session 3: Highlights from ESGO and IGCS

14h20-14h50 Highlights from ESGO 2023

14h50-15h20 Highlights from IGCS 2023

15h20-15h35 Discussion

Session 4: Uterine Neoplasms - State of Art Session -1

15h35-15h55 The changing classification and staging of endometrial cancer

15h55-16h15 Fertility sparing strategies in early endometrial cancer: How to optimize patients' selection?

16h15-16h35 Updates in the management of early endometrial cancer

16h35-16h55 Uterine manipulator during MIS for endometrial cancer: Is it safe?

16h55-17h05 Discussion

17h05-17h20

COFFEE BREAK

Session 5: Uterine Neoplasms - State of Art Session - 2

17h20-17h35 Adjuvant treatment of endometrial cancer: Molecular subtypes and treatment implications

17h35-17h50 Paradigm changes in the treatment of advanced and recurrent endometrial cancer

17h50-18h10 Principles of surgery in uterine sarcomas

18h10-18h25 Updates on adjuvant treatment of uterine sarcoma

18h25-18h40 Discussion

PROGRAM

Friday 8th, December 2023

	Session 1 Epithelial Ovarian Cancer (EOC) - I
9h30-9h50	Molecular profile and classification of EOC
9h50-10h10	Updates in the management of borderline ovarian tumors
10h10-10h30	Management of low-grade serous carcinoma
10h30-10h50	Fertility sparing options in EOC
10.50-11h10	Immunotherapy and Antibody Drug Conjugates (ADCs): How far are we from clinical application?
11h10-11h30	Discussion

	Session 2 Debates in EOC
13h00-13h30	Neoadjuvant chemotherapy vs. primary cytoreduction in EOC (Presidential talk)
13h30-14h00	What is the appropriate approach for the management of recurrent EOC? 13h30-13h45: Surgery (DESKTOP III & SOC-1) 13h45-14h00: Chemotherapy (GOG 213)
14h00-14h20	Is there still a role for HIPEC in the frontline management of advanced EOC? 14h00-14h10: Yes 14h10-14h20: No
14h20-14h30	Discussion

14h30-15h30 LUNCH

	Session 3 Epithelial Ovarian Cancer (EOC) – II
15h30-15h50	Genetic testing and counselling in a limited resource setting
15h50-16h10	Choice of regimens in the first line setting: PARP alone or combination?
16h10-16h30	Recurrent EOC after PARP: What does the evidence say?
16h30-16h45	MEMAGO consensus in EOC: The Roadmap
16h45-17h00	Discussion

17h00-17h15 COFFEE BREAK

	Session 4 Real World Data from the MEMAGO Region
17h15-17h25	Cervical Cancer
17h25-17h35	Endometrial Cancer
17h35-17h45	Ovarian Cancer
17h45-17h55	Gestational Trophoblastic Neoplasia
17h55-18h05	Vulvar Cancer
18h05-18h15	Discussion
18h15- 18h30	Closing Ceremony



www.memago.org